07:00 , Oct 11, 2004 |  BC Week In Review  |  Company News

Chiesi Farmaceutici SpA, Eli Lilly, Icos, Laboratoires Fournier SA, Recordati SpA sales and marketing update

Chiesi Farmaceutici SpA, Parma, Italy   Eli Lilly and Co. (LLY), Indianapolis, Ind.   Icos Corp. (ICOS), Bothell, Wash.   Laboratoires Fournier SA, Dijon, France   Recordati SpA, Milan, Italy   Fournier's Fournier Pharma SA division (Chenove,...
07:00 , Oct 8, 2004 |  BC Extra  |  Company News

Fournier discloses marketing deals

Laboratoires Fournier (Dijon, France) said its Fournier Pharma division received a license from Recordati (Milan, Italy) to market its Zanidip lercanidipine oral calcium-channel blocker to treat hypertension in Indonesia, Vietnam and other Asian countries. Fournier...
08:00 , Mar 8, 1999 |  BC Week In Review  |  Clinical News

Biovail Corp. International regulatory update

Canada granted marketing approval for BVF's Brexidol piroxicam-beta-cyclodextrin, a non-steroidal anti-inflammatory drug (NSAID) to treat mild to severe acute pain. BVF's Crystaal division will market Brexidol in Canada Biovail Corp. International (BVF), Toronto, Ontario...
08:00 , Mar 23, 1998 |  BC Week In Review  |  Company News

Biovail Corp. International, Chiesi Group deal

BVF’s Crystaal Corp. subsidiary received an exclusive license to market in Canada Chiesi’s Brexidol piroxicam, a non-steroidal anti-inflammatory agent to relieve mild to severe acute pain. Brexidol has the same active ingredient as Pfizer’s...